Jianjun Zhao MD, PhD.

Studying multiple myeloma and antibody/nanobody development, chemo/radio-therapy related nephro/cardio/oto-toxicity, DNA damage repair genes. Tweets are my own.

[Jay Bradner, M.D. @jaybradner]

Northern Lights over Iowa this evening. A geomagnetic storm to defy the notion of Fly-Over States.

[Yüksel Ürün @DrYukselUrun]

Is high tumor mutational burden (TMB) always a ticket to immune response?
🧬 New study reveals that mismatch repair deficiency (MMRd) doesn't always lead to immune activation in cancer. It's not just about TMB, but the nature and distribution of mutations matter! 🔍
@NatureGenet @OncoAlert #Immunology #precisionmedicine @jsoriamd @EricTopol #Cancer @tompowles1 @Innov_Medicine @Uromigos

[Pashtoon Kasi MD, MS @pashtoonkasi]

While we talk about time & financial toxicity, ☝🏾thing that’s finally official after a lot of advocacy is

OXALIPLATIN

1️⃣mg/m2/min
🆚
arbitrarily over 2 hours➖1️⃣2️⃣0️⃣ minutes.

👍🏾@AndreaCercek Dr. Saltz @ASCO @JCOOP_ASCO 2016!

Let’s challenge dogma!
Let me know if you do this.

[Jianjun Zhao MD, PhD. @zhao_jianjun]

@lundpa donate to addgene is a good option for them to continue to contribute to research.

[C. Ola Landgren, M.D. @DrOlaLandgren]

In 2023, we will be launching an AI-based individual risk model which can predict clinical outcomes for newly diagnosed myeloma patients (called "IRMMa")

We plan to make this new PRECISION MEDICINE tool available for FREE to myeloma patients and physicians worldwide. Stay tuned!

[Nour Moukalled @nourmoukalled]

Summary of mechanisms of resistance to CAR #COMy23 @COMyCongress

[Linghua Wang, MD, PhD @IamLinghua]

Try this tool just posted ⁦online. It integrates spatial transcriptomics and histology images to annotate tumor and TME cells at super resolution. So thankful to be part of this brilliant team⁦ @DrMingyaoLi⁩ ⁦@DrJianHu⁩⁦@humam_kadara⁩ https://t.co/irtlk0Xhq1

[C. Ola Landgren, M.D. @DrOlaLandgren]

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Innovative translational science published in ⁦@Nature⁩

#mmsm ⁦@theMMRF⁩ ⁦@IMFmyeloma⁩ ⁦@HealthtreeMM⁩ ⁦@SylvesterCancer⁩ https://t.co/x0w8IBw3WC

[Julia Li @JuliaszLi]

I am excited to share that my postdoctoral research is out online today! The unexpected discovery that the EBV-encoded EBNA1 breaks a fragile site on chromosome 11 by binding to a cluster of EBV-like repeats. @nature @UCSanDiego @DamonRunyon https://t.co/ekXgZucG5S

[HealthTree Foundation @HealthTree]

TODAY! 🗓️ Join @JoshuaRichterMD myeloma specialist, as he shares information regarding #immunotherapies targeting #BCMA . Register and join us here: https://t.co/hoMg6nQRTS
#HealthTreeMM #myeloma #multiplemyeloma #mmsm

[Gareth Morgan @DrGarethMorgan1]

Congratulations to Marc Raab and team for seeing this through; great data. A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma | Blood | American Society of Hematology https://t.co/amRlvHpFmq

[Raad Chowdhury, MD, FASN @rc_oncneph]

Our @ndtsocial editorial on "nephrotoxicity" of bortezomib in #Myeloma

🙏🏽 to have 🌎 experts in heme and renal contribute.

A great review of positive heme/renal/patient impact of bortezomib

E. Kastritis
@VincentRK
N. Leung

@MayoClinicNeph

https://t.co/KzQ19HVdtj

[Jianjun Zhao MD, PhD. @zhao_jianjun]

@XShirleyLiu Congrats, Shirley! Such a big breakthrough on humanized antibody discovery using AI.

[Pan-Hammarström lab @panhammarstrom]

Excited to see the paper finally out 😊 Great collaboration with Leng-Siew Yeap at Shanghai Jiao Tong U. and Roberto Chiarle at Harvard U. We dissected the mechanisms that generate rare indels of antibody diversification processes, with implications for the generation of bnAbs

[Bill Dynan - NAR Cancer Editor @NAR_Cancer_EIC]

AP endonuclease 2 (APE2) as an emerging therapeutic target– More from our special collection on DNA repair and cancer therapeutics. From @ShanYanlab @UNCCBiology https://t.co/W4n0eIigh8

[Rémi Buisson @RemiBuisson]

The first virology paper from the lab!!! We discovered that APOBEC3B regulates the innate immune system, promoting translation blockage and protecting stress granules from RNase L during RNA viral infections, independently of its deaminase activity. https://t.co/0ujyPdP8ZX

[Robert W. Sobol @rwsobol]

Thrilled to share our first report on a new polb mouse model and the first mouse polb structure with @AshPrakash5: Polβ/XRCC1 heterodimerization dictates DNA damage recognition and basa... https://t.co/SSJ5z28z9V

[Louis Williams @LouisWilliamsMD]

Anti-CD38 moAb: 3 classes of MOA

1. Fc Mediated: ADCC (NK cells), CDC (C1q - Fc), ADPC (macrophage/ professional APC

2. Direct effects - apoptosis via caspases, lysosomal cell death (Isa > dara)

3. Immunomodulatory - elimination of CD38+ t-reg, MDSC etc. #mmsm

[Jianjun Zhao MD, PhD. @zhao_jianjun]

@LiuCluster @AmericanCancer @lwelmore0320 @NUFeinbergMed @LurieCancer Congratulations! Well deserved!

[Alexis Lomakin, Ph.D. (אל) אַלעקסיס לאָמאַקין @Alexis_Lomakin]

https://t.co/LvHnrcePuF